about
Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataAbbie Lathrop, the "mouse woman of Granby": rodent fancier and accidental genetics pioneerWalter Hess—Nobel Prize for work on the brainNew strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practiceAcquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignanciesCongenital sideroblastic anemia associated with germline polymorphisms reducing expression of FECHFrederick Soddy--pioneer in radioactivityThe well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group.A cello for Michayla.Charles Townes—nobel laureate for maser-laser work.Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.Littoral cell angioma associated with portal hypertension and resected colon cancer.JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome.Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria.Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia I ultrastructure.Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia II. Cytochemistry.Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)Stress-induced hematopoietic failure in the absence of immediate early response gene X-1 (IEX-1, IER3)Physician-poet William Carlos Williams--"no ideas but in things".Niche-based screening identifies small-molecule inhibitors of leukemia stem cellsAdvanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin.Aleksandr Prokhorov--lasers and masers.A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.Charles K. Kao—father of fiber optics.Sidney Altman--Nobel laureate for work with RNAStamp vignette on medical science. William F. Giauque--Nobel Prize for low-temperature research.Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemiaCytogenetic and molecular genetic aspects of essential thrombocythemia.Flow cytometric methods for detection and quantification of apoptosis.Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.The chronic myeloproliferative disorders: an historical perspective.Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based surveyHans Geiger-German physicist and the Geiger counterA genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.Management of anemia in patients with cancer.
P50
Q24240202-A31C7C35-CDE2-49F6-913B-66BB0028E39DQ24242864-CF718655-002B-4843-9DBF-27375230C73FQ24620685-7BC33B2F-181C-43D3-8F91-16E49645D94DQ24635332-4B7A61C8-459A-4DE5-B702-E867E5FEEF6CQ27016511-558CBB55-D19C-4825-8AFF-6E1C4AD64BE6Q28281385-D665D249-6BD2-4DF2-8FA0-75A98FB723D7Q28290665-8DC0764C-8511-4969-BA5C-20040DB3FC89Q28744143-F55355E2-EA5F-413A-81D5-8CE5FFEDB9E3Q30350388-57D44DDB-8E56-4CF9-81A9-1959B8EE36C3Q30549995-68563579-979A-4C9D-993C-6FA84AFD428CQ31031931-9A092708-E3DB-4063-BC5E-3603B77C3752Q33148268-10ACA086-43C4-4EA1-81E2-424120F3F426Q33335660-A74EA6F3-8DAB-4763-B892-89803C0C03B2Q33341856-09A934F4-7A51-460C-A807-DC77968B5674Q33345998-E0AF6976-39D5-4F57-98EC-53CE2A4420E8Q33348507-EFA05E08-8631-41DB-9D72-695CAA9EBA19Q33373506-FD9AEA91-B955-467C-9DF9-95A2F627E66BQ33375428-892929E2-16F2-43C7-A05E-AAD3A9086F9DQ33376466-09DB0166-9958-4892-8C13-5A4F6B6CE4EEQ33401001-1AAED0C9-5042-4F8C-B9F3-1949D4B8B62FQ33410496-5D71435B-A8A9-49F5-90C9-A69414363857Q33461201-8D477858-63FE-43AE-B200-44F7D2D04D26Q33563509-0B1A87B7-46AF-486C-A5F4-B572EC30BC97Q33750384-61BB9FFD-5A70-4D51-9FCB-DA1CDBE1176AQ33937103-64D35967-1C43-41B8-A47D-CE62BC22F371Q34210099-C4E7B4BA-8E2B-4881-BAD3-D8DF4157FBC2Q34216552-3B8862A5-3DA9-439D-9269-24275AC21395Q34303917-FD493F20-A5FE-4B76-B69B-D55A11F01202Q34527220-C0C3CBA3-AD5F-4FEB-8088-05DA3B4A48B7Q34545723-42251899-78E8-41F6-B447-3CCA466A8E7DQ34662889-49BC443F-BF85-4484-A1B8-C3A9CA5C761EQ34789405-B2F2AD3A-8030-47D7-A193-A94EAC9399D8Q35112951-AC8E9252-E46D-4B38-905F-EF9F346B003DQ35168115-434E68D5-3377-441F-9140-459EBFA49901Q35193379-1DB41636-8C9C-497E-836F-94C642AC7CF5Q35528633-12886E12-0AEE-41C8-9F3F-BB4870A69D80Q35584980-185A0C84-B7F4-4F89-9325-49F90DDF0E36Q35586395-84C8F547-DC10-401F-BCE6-C6227ECC3AD5Q35690609-3B04823A-EF5A-49F7-8627-68EDEBB2D78CQ35783062-29CE9E21-881A-499E-A1AC-3387BAC83AA1
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
David P Steensma
@de
David P Steensma
@fr
David P Steensma
@nl
David P Steensma
@sl
David P. Steensma
@en
David P. Steensma
@es
type
label
David P Steensma
@de
David P Steensma
@fr
David P Steensma
@nl
David P Steensma
@sl
David P. Steensma
@en
David P. Steensma
@es
altLabel
David Steensma
@en
prefLabel
David P Steensma
@de
David P Steensma
@fr
David P Steensma
@nl
David P Steensma
@sl
David P. Steensma
@en
David P. Steensma
@es
P214
P244
P106
P1153
7005639226
P21
P213
0000 0000 4021 2826
P214
P244
n2008183464
P31
P496
0000-0001-5130-9284
P734
P735
P7859
lccn-n2008183464